India clears Varian's Halcyon radiation therapy system
Varian Medical Systems' Halcyon radiation therapy system has received the Atomic...Read more on AuntMinnie.comRelated Reading: Varian acquires Mobius Medical Varian inks deal to acquire Sirtex for $1.3B Varian posts double-digit Q1 gain Varian pursues partnership in China Taiwan clears Varian's radiation therapy system
Condition: Glioblastoma Interventions: Radiation: Re-irradiation (RT); Drug: Bevacizumab; Drug: Nivolumab; Procedure: Re-resection Sponsor: Memorial Sloan Kettering Cancer Center Recruiting
ConclusionsIn spine SBRT with the emphasis on preservation of critical neural structures, the target prescribed dose should be defined by using multiple dose-volume objectives to minimize user and apparatus-dependent dose variabilities for the spinal metastases that are adjacent to the critical neural structures.
Publication date: Available online 15 November 2018Source: Stem Cell ReportsAuthor(s): Dengbo Ji, Tiancheng Zhan, Ming Li, Yunfeng Yao, Jinying Jia, Haizhao Yi, Meng Qiao, Jinhong Xia, Zhiqian Zhang, Huirong Ding, Can Song, Yong Han, Jin GuSummaryChemo-/radiotherapy resistance is the main cause accounting for most treatment failure in colorectal cancer (CRC). Tumor-initiating cells (TICs) are the culprit leading to CRC chemo-/radiotherapy resistance. The underlying regulation mechanism of TICs in CRC remains unclear. Here we discovered that miR-15b expression positively correlated with therapeutic outcome in CRC. Expressio...
Heart failure and breast cancer have shared risks and morbidities. Multimodality therapies for breast cancer, including conventional chemotherapy, targeted therapeutics, radiation therapy, and hormonal agents, may make patients more susceptible to asymptomatic left ventricular dysfunction and clinical heart failure during and after treatment. New or preexisting left ventricular dysfunction may lead to interruptions in cancer treatment and limit options of breast cancer systemic therapy, leading to adverse outcomes. Early recognition and management of cardiovascular risk factors before, during, and after cancer treatment ar...
AbstractRecent studies have examined the impact of phosphodiesterase type 5 inhibitors (PDE5 ‐Is) use on the risk of prostate cancer, and biochemical recurrence (BCR) in prostate cancer patients, but the results were inconsistent. A meta‐analysis was conducted to assess the associations with all published studies. Databases (PubMed, Web of Science and MEDLINE) were retrieved to identify relevant studies which explored the impact of PDE5‐Is use on the risk of prostate cancer, and BCR in prostate cancer patients. The summary results along with 95% confidence intervals (CIs) were calculated. Nine articles were eligible ...
A husband-and-wife physician team at the University of Virginia (UVA) Cancer...Read more on AuntMinnie.comRelated Reading: UVA joins forces with Foundation Radiology Group UVA launches focused ultrasound trial for epilepsy UVA developing breast screening model UVA buys Elekta's Leksell IMRIS signs UVA
ConclusionsMMRs are not systematically implemented in RT departments worldwide. In France and in Europe, few departments with quality assurance programs have implemented MMRs. This survey showed that a large majority of centers are interested in implementing an MMR with a formalized procedure. Our project could help increase the interest of the RT community worldwide in this topic.
Condition: Colorectal Cancer Interventions: Drug: Probiotic Formula Capsule; Drug: Placebos Sponsors: University of Jordan; King Hussein Cancer Center Recruiting
Swedish nuclear medicine software developer Hermes Medical Solutions has released...Read more on AuntMinnie.comRelated Reading: Hermes appoints new president, CEO Hermes launches new liver analysis software Hermes expands North America executive team Hermes, Vanderbilt collaborate on dosimetry application Hermes gets FDA nod for NM software
(University of Virginia Health System) Husband-and-wife doctors have been awarded more than $1.8 million for their effort to improve radiation therapy and breast surgery for patients with early-stage breast cancer.